Topoisomerase IIa gene amplification predicts favorable outcome of tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2 positive breast cancer. Results from the randomized trial SBG 9401.

Research output: Contribution to journal › Published meeting abstract

Standard

Topoisomerase IIa gene amplification predicts favorable outcome of tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2 positive breast cancer. Results from the randomized trial SBG 9401. / Tanner, MM; Isola, JJ; Wiklund, T; Erikstein, B; Kellokumpu-Lehtinen, P; Malmström, Per; Wilking, N; Nilsson, J; Bergh, J.

In: Journal of Clinical Oncology, Vol. 23, No. 16S, 2005, p. 841S-841S.

Research output: Contribution to journal › Published meeting abstract

Harvard

Tanner, MM, Isola, JJ, Wiklund, T, Erikstein, B, Kellokumpu-Lehtinen, P, Malmström, P, Wilking, N, Nilsson, J & Bergh, J 2005, 'Topoisomerase IIa gene amplification predicts favorable outcome of tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2 positive breast cancer. Results from the randomized trial SBG 9401.', Journal of Clinical Oncology, vol. 23, no. 16S, pp. 841S-841S.

APA

Tanner, MM., Isola, JJ., Wiklund, T., Erikstein, B., Kellokumpu-Lehtinen, P., Malmström, P., ... Bergh, J. (2005). Topoisomerase IIa gene amplification predicts favorable outcome of tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2 positive breast cancer. Results from the randomized trial SBG 9401. Journal of Clinical Oncology, 23(16S), 841S-841S.

CBE

Tanner MM, Isola JJ, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmström P, Wilking N, Nilsson J, Bergh J. 2005. Topoisomerase IIa gene amplification predicts favorable outcome of tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2 positive breast cancer. Results from the randomized trial SBG 9401. Journal of Clinical Oncology. 23(16S):841S-841S.

MLA

Tanner, MM et al. "Topoisomerase IIa gene amplification predicts favorable outcome of tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2 positive breast cancer. Results from the randomized trial SBG 9401.". Journal of Clinical Oncology. 2005, 23(16S). 841S-841S.

Vancouver

Tanner MM, Isola JJ, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmström P et al. Topoisomerase IIa gene amplification predicts favorable outcome of tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2 positive breast cancer. Results from the randomized trial SBG 9401. Journal of Clinical Oncology. 2005;23(16S):841S-841S.

Author

Tanner, MM ; Isola, JJ ; Wiklund, T ; Erikstein, B ; Kellokumpu-Lehtinen, P ; Malmström, Per ; Wilking, N ; Nilsson, J ; Bergh, J. / Topoisomerase IIa gene amplification predicts favorable outcome of tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2 positive breast cancer. Results from the randomized trial SBG 9401. In: Journal of Clinical Oncology. 2005 ; Vol. 23, No. 16S. pp. 841S-841S.

RIS

TY - JOUR

T1 - Topoisomerase IIa gene amplification predicts favorable outcome of tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2 positive breast cancer. Results from the randomized trial SBG 9401.

AU - Tanner, MM

AU - Isola, JJ

AU - Wiklund, T

AU - Erikstein, B

AU - Kellokumpu-Lehtinen, P

AU - Malmström, Per

AU - Wilking, N

AU - Nilsson, J

AU - Bergh, J

PY - 2005

Y1 - 2005

M3 - Published meeting abstract

VL - 23

SP - 841S-841S

JO - Journal of clinical oncology : official journal of the American Society of Clinical Oncology

T2 - Journal of clinical oncology : official journal of the American Society of Clinical Oncology

JF - Journal of clinical oncology : official journal of the American Society of Clinical Oncology

SN - 1527-7755

IS - 16S

ER -